Recent Security Class Actions

Altimmune Inc. Common Stock (NASDAQ: ALT)

46 Days left to seek lead plaintiff status.

Company Name:Altimmune Inc. Common Stock
Stock Symbol:NASDAQ: ALT
Class Period Start:12/01/2023
Class Period End (inclusive):04/26/2024
Filing Deadline:07/05/2024

The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) Altimmune overstated the potential for pemvidutide to stand out from competing GLP-1 agonists based on the drug's efficacy and tolerability results observed in the MOMENTUM Trial; (ii) accordingly, the MOMENTUM Trial results were less significant to pemvidutide's clinical, commercial, and competitive prospects than Defendants had led investors to believe; (iii) as a result of all the foregoing, Defendants had overstated Altimmune's prospects for finding a strategic partner to develop pemvidutide; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Altimmune Inc. Common Stock (NASDAQ: ALT) Claim Form

Name(Required)
Address
This field is for validation purposes and should be left unchanged.